Epidarex Portfolio News

18 Mar

21

Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

In All, Portfolio

Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in hemoglobin levels and showed improvements in key clinical outcomes Marketing applications for pegcetacoplan are under Priority Review with the FDA and under review with the…

10 Mar

19

Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy

In All, Portfolio

Data published in Ophthalmology and the American Journal of Ophthalmology underscore the potential of pegcetacoplan, an investigational targeted C3 therapy, for geographic atrophy WALTHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) —  Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that two…

05 Feb

10

LUNAC Therapeutics Wins Start Up of the Year at Bionow Awards

In All, Portfolio

Leeds, UK, 5 February 2021:  LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the development of advanced life-saving anticoagulants, has been named as this year’s Start Up of the Year winner at the 19th Bionow Awards.  The 19th Bionow Awards took place…

19 Jan

108

Slate Bio Launches with Seed Financing to Develop Next Generation IL-2 Therapies

In All, Portfolio

CHARLOTTESVILLE, Va. —Slate Bio, Inc., announced today the closing of a $1.75 million venture financing. Epidarex Capital led the investment round with participation from the UVA Licensing & Ventures Group Seed Fund, Center for Innovative Technology’s GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., management and others….

07 Jan

42

Theolytics raises $7 million Series A co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies

In All, Portfolio

Oxford, UK, 7th January 2020 – Theolytics, a UK biotech harnessing viruses to combat cancer, today announced the closing of a US $7 million (UK £5 million) Series A round. The financing was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing…

15 Dec

22

NodThera Appoints Chief Medical Officer and Chief Financial Officer

In All, Portfolio

Strengthens senior leadership team with appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton, J.D., MBA, as Chief Financial Officer CAMBRIDGE, UK, BOSTON and SEATTLE – December 15, 2020 – NodThera, a biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome…

10 Dec

22

Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH

In All, Portfolio

Treatment with pegcetacoplan resulted in a sustained improvement in hemoglobin with a mean increase from baseline of 2.7 g/dL at Week 48, which is equal to the 2.7 g/dL increase seen at Week 16 with pegcetacoplan-treated patients Sustained improvements in transfusion avoidance, reticulocyte count, lactate…

07 Dec

10

Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-Life Improvements Compared to C5 Inhibitors for PNH

In All, Portfolio

Data were presented at the American Society of Hematology (ASH) Annual Meeting In an analysis from the 16-week Phase 3 PEGASUS study, 70.7% of patients treated with pegcetacoplan compared to 5.1% of eculizumab-treated patients achieved a good, major, or complete hematologic response based on published classifications Quality–of–life substantially improved for pegcetacoplan-treated patients, reaching near-normal levels on several measures, and did not change for eculizumab-treated patients in a PEGASUS analysis at 16 weeks A matching–adjusted indirect…